Clinical Trial Update: Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Secukinumab (AIN457) in patients with rotator cuff tendinopathy has completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotator Cuff Tendinopathy

Drugs mentioned

• Secukinumab (AIN457) (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tendinopathy | Phase 3 | Status: COMPLETED | Results posted: 2025-12-02